All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2010-022266-27||Long term immunity and safety following vaccination with the Japanese Encephalitis vaccine IC51 (IXIARO®, JESPECT®) in a pediatric population in non-endemic countries. Uncontrolled, Phase 3 Follow-up ...||2014-09-15||due-trials|
|Reported results||2011-004771-36||A CONFIRMATORY PHASE II/III STUDY ASSESSING EFFICACY, IMMUNOGENICITY AND SAFETY OF IC43 RECOMBINANT PSEUDOMONAS VACCINE IN INTENSIVE CARE PATIENTS.||2015-12-29||due-trials|
|Reported results||2014-003934-22||DOSE-CONFIRMATION, IMMUNOGENICITY AND SAFETY STUDY OF THE CLOSTRIDIUM DIFFICILE VACCINE CANDIDATE VLA84 IN HEALTHY ADULTS AGED 50 YEARS AND OLDER. RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE II STUD...||2015-10-15||due-trials|
|Reported results||2018-003379-37||IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BL...||2020-10-02||due-trials|
|Ongoing||2022-000035-23||OPEN-LABEL PHASE 3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN VOLUNTEERS AGED ≥18 YEARS, AFTER NATURAL SARS-COV-2 INFECTION OR RECEIPT OF NATION...||not-yet-due|